Citations

Showing 10 of 108119 citations.

Longitudinally Increasing Elevated Asymmetric Flortaucipir Binding in a Cognitively Unimpaired Amyloid-Negative Older Individual
Schwarz, Christopher G., Knopman, David S., Ramanan, Vijay K., Lowe, Val J., Wiste, Heather J., Cogswell, Petrice M., Utianski, Rene L., Senjem, Matthew L., Gunter, Jeffrey R., Vemuri, Prashanthi, Petersen, Ronald C., Jack, Clifford R., Jack, Clifford R. , Senjem, Matthew L. , Vemuri, Prashanthi , Jack, Clifford R , Vemuri, Prashanthi , Senjem, Matthew L , Schwarz, Christopher G., Knopman, David S., Ramanan, Vijay K., Lowe, Val J., Wiste, Heather J., Cogswell, Petrice M., Utianski, Rene L., Gunter, Jeffrey R., Petersen, Ronald C.

Mayo Clinic

Journal of Alzheimer's Disease | November 9, 2021 | Volume: 85 | Issue: 1 | Pages: 59-64

10.3233/jad-215052 | PMID 34776445 Get It

We present the case of a cognitively unimpaired 77-year-old man with elevated, asymmetric, and longitudinally increasing Flortaucipir tau PET despite normal (visually negative) amyloid PET. His atypical tau PET signal persisted and globally increased in a follow-up scan five years later. Across eight years of observations, temporoparietal atrophy was observed consistent with tau PET patterns, but he retained the cognitively unimpaired classification. Altogether, his atypical tau PET signal is not explained by any known risk factors or alternative pathologies, and other imaging findings were not remarkable. He remains enrolled for further observation.
Connecting Cohorts to Diminish Alzheimer’s Disease (CONCORD-AD): A Report of an International Research Collaboration Network
Pavlik, Valory N., investigators, for the CONCORD-AD, Burnham, Samantha C., Kass, Joseph S., Helmer, Catherine, Palmqvist, Sebastian, Vassilaki, Maria, Dartigues, Jean-François, Hansson, Oskar, Masters, Colin L., Pérès, Karine, Petersen, Ronald C., Stomrud, Erik, Butler, Lesley, Coloma, Preciosa M., Teitsma, Xavier M., Doody, Rachelle, Sano, Mary, Masters, Colin L. , Helmer, Catherine , Hansson, Oskar , Palmqvist, Sebastian , Stomrud, Erik , Stomrud, Erik , Hansson, Oskar , Masters, Colin L , Pavlik, Valory N., investigators, for the CONCORD-AD, Burnham, Samantha C., Kass, Joseph S., Vassilaki, Maria, Dartigues, Jean-François, Pérès, Karine, Petersen, Ronald C., Butler, Lesley, Coloma, Preciosa M., Teitsma, Xavier M., Doody, Rachelle, Sano, Mary

Mayo Clinic

Journal of Alzheimer's Disease | November 9, 2021 | Volume: 85 | Issue: 1 | Pages: 31-45

10.3233/jad-210525 | PMID 34776434 Get It

Longitudinal observational cohort studies are being conducted worldwide to understand cognition, biomarkers, and the health of the aging population better. Cross-cohort comparisons and networks of registries in Alzheimer’s disease (AD) foster scientific exchange, generate insights, and contribute to the evolving clinical science in AD. A scientific working group was convened with invited investigators from established cohort studies in AD, in order to form a research collaboration network as a resource to address important research questions. The Connecting Cohorts to Diminish Alzheimer’s Disease (CONCORD-AD) collaboration network was created to bring together global resources and expertise, to generate insights and improve understanding of the natural history of AD, to inform design of clinical trials in all disease stages, and to plan for optimal patient access to disease-modifying therapies once they become available. The network brings together expertise and data insights from 7 cohorts across Australia, Europe, and North America. Notably, the network includes populations recruited through memory clinics as well as population-based cohorts, representing observations from individuals across the AD spectrum. This report aims to introduce the CONCORD-AD network, providing an overview of the cohorts involved, reporting the common assessments used, and describing the key characteristics of the cohort populations. Cohort study designs and baseline population characteristics are compared, and available cognitive, functional, and neuropsychiatric symptom data, as well as the frequency of biomarker assessments, are summarized. Finally, the challenges and opportunities of cross-cohort studies in AD are discussed.
Mogamulizumab in Combination with Nivolumab in a Phase I/II Study of Patients with Locally Advanced or Metastatic Solid Tumors
Hong, David S. , Rixe, Olivier, Chiu, Vi K., Forde, Patrick M., Dragovich, Tomislav, Lou, Yanyan , Nayak-Kapoor, Asha , Leidner, Rom , Atkins, James N., Collaku, Agron , Fox, Floyd E., Marshall, Margaret A. , Forde, Patrick M. , Olszanski, Anthony J , Hong, David S , Forde, Patrick , Rixe, Olivier, Chiu, Vi K., Dragovich, Tomislav, Lou, Yanyan , Nayak-Kapoor, Asha , Leidner, Rom , Atkins, James N., Collaku, Agron , Fox, Floyd E., Marshall, Margaret A.

Mayo Clinic

Clinical Cancer Research | November 9, 2021 | Volume: 28 | Issue: 3 | Pages: 479-488

10.1158/1078-0432.ccr-21-2781 | PMID 34753777 Get It

Abstract Purpose: The aim of the study was to determine safety, antitumor activity, and pharmacodynamic profile of mogamulizumab, an anti-CCR4 monoclonal antibody targeting effector regulatory T cells (Treg) in combination with the checkpoint inhibitor nivolumab in patients with locally advanced or metastatic solid tumors. Patients and Methods: This was a multicenter, dose-finding (phase I), and dose expansion (phase II) study (NCT02705105) in patients with locally advanced or metastatic solid tumors. There were no dose-limiting toxicities in phase I with mogamulizumab 1 mg/kg every week for cycle 1 followed by 1 mg/kg every 2 weeks plus nivolumab 240 mg every 2 weeks intravenously, and cohort expansion occurred at this dose level. Results: All 114 patients treated with mogamulizumab 1 mg/kg plus nivolumab 240 mg in phases I (n = 4) and II (n = 110) were assessed for safety and efficacy. Mogamulizumab plus nivolumab showed acceptable safety and tolerability. Objective response rate was 10.5% [95% confidence interval (CI), 5.6–17.7; 3 complete and 9 partial responses]. Disease control rate was 36.8%. Median duration of response was 14.4 months. Median progression-free survival was 2.6 (95% CI, 2.3–3.1) months, and median overall survival was 9.5 (95% CI, 5.9–13.5) months. Conclusions: Combination of mogamulizumab with nivolumab for treatment of patients with locally advanced or metastatic solid tumors did not result in enhanced efficacy. Tolerability of mogamulizumab 1 mg/kg plus nivolumab 240 mg was acceptable.
T cell–derived tumor necrosis factor induces cytotoxicity by activating RIPK1-dependent target cell death
Chun, Nicholas , Ang, Rosalind L. , Chan, Mark , Horwitz, Julian K. , Gelles, Jesse D. , Chipuk, Jerry E. , Kelliher, Michelle A. , Pavlov, Vasile I., Li, Yansui , Homann, Dirk , Ting, Adrian T. , Chun, Nicholas , Fairchild, Robert L. , Baldwin, William M. , Heeger, Peter S.

Mayo Clinic

JCI Insight | November 9, 2021 | Volume: 6 | Issue: 24 | Pages: No page available

10.1172/jci.insight.148643 | PMID 34752416 Get It

TNF ligation of TNF receptor 1 (TNFR1) promotes either inflammation and cell survival by (a) inhibiting RIPK1’s death-signaling function and activating NF- κ B or (b) causing RIPK1 to associate with the death-inducing signaling complex to initiate apoptosis or necroptosis. The cellular source of TNF that results in RIPK1-dependent cell death remains unclear. To address this, we employed in vitro systems and murine models of T cell–dependent transplant or tumor rejection in which target cell susceptibility to RIPK1-dependent cell death could be genetically altered. We show that TNF released by T cells is necessary and sufficient to activate RIPK1-dependent cell death in target cells and thereby mediate target cell cytolysis independently of T cell frequency. Activation of the RIPK1-dependent cell death program in target cells by T cell–derived TNF accelerates murine cardiac allograft rejection and synergizes with anti-PD1 administration to destroy checkpoint blockade–resistant murine melanoma. Together, the findings uncover a distinct immunological role for TNF released by cytotoxic effector T cells following cognate interactions with their antigenic targets. Manipulating T cell TNF and/or target cell susceptibility to RIPK1-dependent cell death can be exploited to either mitigate or augment T cell–dependent destruction of allografts and malignancies to improve outcomes.
944 Fibroblasts as paracrine targets of the oncometabolite D-2-HG in the IDH1-mutant cholangiocarcinoma tumor microenvironment
Jain, Prerna , Mody, Kabir , El-Refai, Sherif , Zabransky, Daniel J. , Jaffee, Elizabeth M. , Yarchoan, Mark

Mayo Clinic

Regular and Young Investigator Award Abstracts | November 9, 2021 | Volume: No volume available | Issue: No issue available | Pages: A991-A992

10.1136/jitc-2021-sitc2021.944 Get It

960 Randomized multicenter study of neoadjuvant chemoradiation therapy (CRT) alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic cancer
Rahma, Osama E. , Bauer, Todd W. , Wolpin, Brian M. , Stucky, Chee‐Chee , Dias-Costa, Andressa, Patrick, Lenehan, Petroni, Gina R. , Dougan, Stephanie K. , Slingluff, Craig L. , Bauer, Todd W , Katz, Matthew H. G. , Bekaii‐Saab, Tanios , Elias, Rawad , Nowak, Jonathan A.

Mayo Clinic

Late-Breaking Abstracts | November 9, 2021 | Volume: No volume available | Issue: No issue available | Pages: A1010-A1010

10.1136/jitc-2021-sitc2021.960 Get It

897 Infusion episode-related benefits of pembrolizumab Q6W dosing schedule for patients with melanoma treated in the adjuvant and metastatic settings in the United States (US)
Aguiar‐Ibáñez, Raquel , Scherrer, Emilie , Grebennik, Dmitri, Khandelwal, Anvi, Cook, John, Bagga, Shalini, Sawhney, Baanie , Soefje, Scott A.

Mayo Clinic

Regular and Young Investigator Award Abstracts | November 9, 2021 | Volume: No volume available | Issue: No issue available | Pages: A941-A941

10.1136/jitc-2021-sitc2021.897 Get It

542 Randomized trial of tumor lysate particle only vaccine vs. tumor lysate particle-loaded, dendritic cell vaccine to prevent recurrence of resected stage III/IV melanoma: 36-month analysis
Carpenter, Elizabth, Adams, Lexy, Vreeland, Timothy J. , Valdera, Franklin, McCarthy, Patrick M. , Hale, Diane F. , Bohan, Phillip Kemp, Hickeron, Annelies, Myers, John , Cindass, Jessica L., Hyngstrom, John , Berger, Adam C. , Shaheen, Montaser , Yu, Xianzhong, Wagner, Thomas E., Faries, Mark B. , Peoples, George E. , McCarthy, Patrick , Chick, Robert C. , Clifton, Guy T. , O’Shea, Anne E. , Bohan, Phillip M. Kemp , Sussman, Jonathan , Jakub, James W.

Mayo Clinic

Regular and Young Investigator Award Abstracts | November 9, 2021 | Volume: No volume available | Issue: No issue available | Pages: A571-A571

10.1136/jitc-2021-sitc2021.542 Get It